Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-915275 是口服有效的人 11β-羟基类固醇脱氢酶1型选择性抑制剂,Ki 为 2.3 nM,在 HEK293 细胞中的EC50为 15 nM 。它对人和猴原代肝细胞中可的松向皮质醇的转化具有剂量依赖性,EC50分别为 20 nM 和 100 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 315 | 现货 | ||
2 mg | ¥ 453 | 现货 | ||
5 mg | ¥ 722 | 现货 | ||
10 mg | ¥ 927 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 3,650 | 现货 | ||
100 mg | ¥ 5,680 | 现货 | ||
500 mg | ¥ 11,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 815 | 现货 |
产品描述 | PF-915275 is an effective and selective inhibitor of human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1, Ki = 2.3 nM, EC50 = 15 nM in vitro HEK293 cells). The dose-dependent effect of PF-915275 on conversion of cortisone to cortisol in primary human and monkey hepatocytes, with an EC50 of 20 and 100 nM, respectively. |
靶点活性 | 11β-HSD1:15 nM(EC50), 11β-HSD1:2.3 nM(Ki) |
体外活性 | PF-915275 is a poor inhibitor of 11βHSD1 in rat FAO hepatoma cells (EC50: 14,500 nM), consistent with the species differences between humans and rodents observed in biochemical assays. PF-915275 is a potent inhibitor of 11βHSD1 (in vitro HEK293, EC50 of 15 nM) in this human 11βHSD1 overexpressed cell line when coincubated in the presence of 300 nM enzyme substrate. PF-915275 does not significantly inhibit 11βHSD2 (only 1.5% inhibition when tested at 10 μM). PF-915275 shows species-dependent potency for inhibiting the cellular conversion of cortisone to cortisol in a dog, monkey, and human in primary hepatocytes, with activity in human hepatocytes/monkey hepatocytes/dog hepatocytes [1]. |
体内活性 | PF-915275 dose-dependently inhibits the 11βHSD1-mediated conversion of prednisone to prednisolone. A maximum of 87% inhibition is observed, with the highest tested dose of 3 mg/kg. The inhibition of either cortisone or prednisone turnover with PF-915275 yields similar EC50 values to that in human hepatocytes (EC50 by PF-915275 is 18 and 13 nM using cortisone and prednisone substrates, respectively) in vivo 11βHSD1 activity. The half-life of PF-915275 is 22 hours in the monkey. Plasma insulin levels are significantly lowered (by 54 and 60%, respectively) at 1 and 3 mg/kg PF-915275 treatment. Plasma glucose or lipid levels are not altered with treatment. PF-915275 (0.1-3 mg/kg; p.o.; for 8 hours; male cynomolgus monkeys) treatment displays a trend in dose-dependent lowering of fed plasma insulin after 8 h of dosing in these monkeys [1]. |
分子量 | 350.39 |
分子式 | C18H14N4O2S |
CAS No. | 857290-04-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31 mg/mL (88.47 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.854 mL | 14.2698 mL | 28.5396 mL | 71.3491 mL |
5 mM | 0.5708 mL | 2.854 mL | 5.7079 mL | 14.2698 mL | |
10 mM | 0.2854 mL | 1.427 mL | 2.854 mL | 7.1349 mL | |
20 mM | 0.1427 mL | 0.7135 mL | 1.427 mL | 3.5675 mL | |
50 mM | 0.0571 mL | 0.2854 mL | 0.5708 mL | 1.427 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PF-915275 857290-04-1 Metabolism Dehydrogenase PF 915275 PF915275 inhibit Inhibitor inhibitor